Investment
Features
FeesSafety
Academy
More
Pluang+

REITs defy rising rates, supported by strong fundamentals and shrinking supply.

Market News
23 Sep 2026
Seeking Alpha
View Source
Bullish
REITs defy rising rates, supported by strong fundamentals and shrinking supply.

Despite the 10-Year Treasury yield hitting 5%, REITs have remained resilient, rising about 7% in 2026. This resilience is driven by solid property-level cash flows, improving earnings visibility, strong dividend coverage, and healthier balance sheets. Additionally, a significant reduction in new REIT developments, except for Data Centers, supports these fundamentals. Public market valuations are improving, narrowing the gap with private market values, which may attract more capital to public REITs and enable them to acquire assets and grow externally.

REITs show resilience in 2026 despite rate shocks. For readers following real estate, here is Pluang's market snapshot as of Sep 23, 2026 21:42 WIB: Of 26 priced real estate-sector US stocks, 3 rose and 23 fell. Notable prices include JLL at USD 331.07 with a -1.28% change, NLY at USD 21.18 with a -1.19% change, and AGNC at USD 9.97 with a -1.14% change. Typical hold times range from 70 to 102 days, with strong buy order activity on Pluang.

More News

GE Aerospace stock could rise 35% as analysts highlight strong backlog and new engine orders.

GE Aerospace stock could rise 35% as analysts highlight strong backlog and new engine orders.

Jefferies analysts set a new price target of $435 for General Electric Aerospace, implying a 35% upside from its current price of around $321. GE Aerospace's strong position is supported by a $170 billion commercial services backlog and 80,000 aircra...

Analyst Insights
Bullish
2 hours ago
BNP Paribas cuts PepsiCo price target to $161, citing demand challenges but keeps Outperform rating.

BNP Paribas cuts PepsiCo price target to $161, citing demand challenges but keeps Outperform rating.

BNP Paribas lowered its price target for PepsiCo from $183 to $161 on September 23, 2026, due to ongoing demand challenges in North America. Despite the cut, the firm maintained an Outperform rating, indicating confidence in the stock's potential. Th...

Analyst Insights
Bearish
3 hours ago
Celldex's price target jumps to $88 after positive Phase III trial for chronic urticaria drug.

Celldex's price target jumps to $88 after positive Phase III trial for chronic urticaria drug.

Celldex Therapeutics saw its price target raised from $70 to $88 by Leerink Partners following successful Phase III trial results for its drug barzolvolimab treating chronic spontaneous urticaria (CSU). The trials met all primary endpoints, showing l...

Analyst Insights
Bullish
3 hours ago
Ero Copper stock holds steady with a raised price target amid plans to boost production by 2028.

Ero Copper stock holds steady with a raised price target amid plans to boost production by 2028.

Ero Copper, a major copper producer, shows stock volatility between $16.88 and $40.83 over the past year. Analyst firm CIBC maintained a "Neutral" rating but increased the price target to C$56.00, reflecting optimism about the company's long-term gro...

Analyst Insights
Bullish
3 hours ago
Cintas reports strong Q1 with EPS $1.39 and revenue up 10.9%, beating estimates.

Cintas reports strong Q1 with EPS $1.39 and revenue up 10.9%, beating estimates.

Cintas Corporation posted robust first-quarter results, surpassing analyst expectations with earnings per share of $1.39 and revenue of $3.01 billion, a 10.9% increase year-over-year. The company's organic revenue growth was 8.9%, reflecting solid bu...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App